Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
I read with interest Mike Renier’s letter to the editor on pyruvate kinase (C&EN, May 17, page 5).
I’m a biochemist, and I have wondered why NAD kinase (only enzyme to produce NADP) has not been targeted for cancer therapy. This approach might be more effective than other kinase inhibitors such as pyruvate kinase.
The pharmaceutical companies have a library of kinase inhibitors. They might want to include NAD kinase inhibitors in their lists.
This article has been sent to the following recipient: